Indonesia’s Food and Drugs Agency (BPOM) has suspended the use of AstraZeneca’s COVID-19 vaccine, the Jakarta Globe reported Monday, March 15.
According to BPOM head Penny Lukito, the use of the 1.1 million vaccines Indonesia received will be suspended pending a recommendation from the World Health Organization (WHO).
“We are waiting for the WHO recommendation as a precautionary measure. The recommendation will be referred to an interagency commission and the health ministry, which will decide when AstraZeneca’s vaccine will be used for nationwide vaccination,” Luquito said.
Earlier on Monday, the use of the AstraZeneca vaccine was also suspended by Spain. Authorities in the autonomous communities of Andalucía, Castilla y Leon and Asturias suspended its use as early as March 12 after reports of an increased risk of thrombosis following vaccination with the AstraZeneca drug.
It was also reported that use of the AstraZeneca vaccine was suspended in Germany, Italy, France, Denmark, Ireland, Iceland, Romania, Bulgaria and the Netherlands.
On March 15 it also became known that in Denmark a patient died after being vaccinated with the drug from AstraZeneca. The country’s medical agency reported similar symptoms to the clinical picture in several reports in European databases. The woman had a low platelet count, blood clots in small and large vessels, and bleeding.
On the same day, Steinar Madsen, director of the Norwegian Medicines Agency, reported that a medic who had previously been hospitalized due to worsening conditions after vaccination with the drug in question had died in Norway.